Techno Medica Co., Ltd. AI Stock Analysis
Want to see JP:6678 full AI Analyst Report?
Techno Medica Co., Ltd. (6678) AI Stock Analysis
Techno Medica Co., Ltd.
(TSE/TYO:6678)
Techno Medica earns a strong overall score driven primarily by its highly attractive valuation, highlighted by a nearly 6% dividend yield and a low P/E ratio. The stock is also supported by robust bullish technical momentum, trading comfortably above all key moving averages. Fundamentally, the company provides a highly stable, zero-debt balance sheet and excellent cash flow generation, which provides a strong safety net despite historically stagnant bottom-line growth.
Techno Medica Co., Ltd. (6678) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 14.09B
- Dividend Yield
- 6.08%
- Average Volume (3M)
- 12.01K
- Price to Earnings (P/E)
- 12.1
- Beta (1Y)
- 0.53
- Revenue Growth
- 17.11%
- EPS Growth
- 23.02%
- Country
- Japan
- Employees
- 239
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Techno Medica Co., Ltd. Business Overview & Revenue Model
Company Description
Techno Medica Co., Ltd. is a Japanese company that specializes in the entire lifecycle of in-vitro diagnostic analyzers, covering their research, development, manufacturing, distribution, and international trade. Their product portfolio includes auto...
How the Company Makes Money
Techno Medica primarily makes money by selling in-vitro diagnostic equipment (analyzers and related laboratory systems) to medical institutions and testing laboratories, and by generating recurring revenue from consumables and reagents used with its...
Techno Medica Co., Ltd. Financial Statement Overview
Summary
Techno Medica maintains a highly stable and conservative financial profile. It boasts a pristine, debt-free balance sheet and excellent cash flow generation with high earnings conversion. While recent revenue shows solid double-digit growth, the score is tempered by stagnant long-term net income, slight margin compression, and modest single-digit returns on equity.
Income Statement
65PositiveBalance Sheet
85Very PositiveCash Flow
80Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.59B | 11.24B | 9.91B | 10.28B | 9.37B | 9.70B |
| Gross Profit | 5.44B | 5.24B | 4.88B | 5.10B | 4.59B | 4.78B |
| EBITDA | 1.96B | 1.76B | 1.40B | 1.95B | 1.76B | 1.96B |
| Net Income | 1.19B | 1.07B | 1.00B | 1.35B | 1.15B | 1.28B |
Balance Sheet | ||||||
| Total Assets | 15.49B | 17.97B | 17.94B | 17.43B | 19.44B | 18.51B |
| Cash, Cash Equivalents and Short-Term Investments | 8.44B | 8.98B | 9.06B | 8.59B | 11.75B | 11.52B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.27B | 3.56B | 3.55B | 3.62B | 3.06B | 2.86B |
| Stockholders Equity | 13.22B | 14.41B | 14.39B | 13.82B | 16.39B | 15.65B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.07B | 952.67M | 1.10B | 748.50M | 2.00B |
| Operating Cash Flow | 0 | 1.10B | 977.53M | 1.14B | 887.24M | 2.06B |
| Investing Cash Flow | 0 | -39.76M | -32.34M | -100.72M | -155.37M | 2.49B |
| Financing Cash Flow | 0 | -1.15B | -470.16M | -4.21B | -505.09M | -598.64M |
Techno Medica Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6678, the sentiment is Neutral. The current price of 2121.00 is below the 20-day moving average (MA) of 2136.35, above the 50-day MA of 2068.40, and below the 200-day MA of 2149.11, indicating a neutral trend. The MACD of 26.67 indicates Positive momentum. The RSI at 50.74 is Neutral, neither overbought nor oversold. The STOCH value of 37.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:6678.
Techno Medica Co., Ltd. Peers Comparison
Overall Rating
JP:667882Outperform
JP:684963Neutral
JP:652361Neutral
JP:796359Neutral
JP:454950Neutral
JP:760045Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 82Outperform | JPY 18.29B | 12.06 | ― | 6.08% | 17.11% | 23.02% | |
| 63Neutral | JPY 254.11B | 20.24 | ― | 2.11% | -0.18% | -33.38% | |
| 61Neutral | JPY 163.74B | 11.33 | 8.71% | 3.27% | 2.74% | 145.33% | |
| 59Neutral | JPY 8.15B | 9.85 | ― | 3.02% | 8.56% | 7.14% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | JPY 73.85B | 40.27 | ― | 2.55% | 3.92% | -52.01% | |
| 45Neutral | JPY 8.06B | -5.03 | ― | 5.56% | -8.68% | -75.03% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:6678 | Techno Medica Co., Ltd. | 2121.00 | 257.42 | 13.81% | |
| JP:6523 | PHC Holdings Corp. | 1286.00 | 348.58 | 37.18% | |
| JP:4549 | Eiken Chemical Co., Ltd. | 2273.00 | 44.34 | 1.99% | |
| JP:6849 | Nihon Kohden Corporation | 1519.00 | 38.53 | 2.60% | |
| JP:7600 | Japan Medical Dynamic Marketing, Inc. | 306.00 | -149.23 | -32.78% | |
| JP:7963 | Koken Ltd. | 1650.00 | -152.47 | -8.46% |
Techno Medica Co., Ltd. Corporate Events
Techno Medica Reports Strong First-Half Earnings Growth
Techno Medica Co., Ltd., a Tokyo-listed company, reported non-consolidated net sales of ¥4.453 billion for the six months ended September 30, 2026, up 8.5% year on year, while operating profit rose 75.7% to ¥468 million and net profit increased 58.2%...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
